Dina Fathalla

Dina Fathalla

Auto-generated profile, based on publicly available information

Dina Fathalla

Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
VCValentina Cipriani
Valentina Cipriani
LLLaura Lorés-Motta
Laura Lorés-Motta
FHFan He
Fan He
DFDina Fathalla
Dina Fathalla
VTViranga Tilakaratna
Viranga Tilakaratna
SCSimon John Clark
Simon John Clark
Age-related macular degeneration (AMD) is a leading cause of blindness. Genetic variants at the chromosome 1q31.3 encompassing the complement factor H (CFH, FH) and CFH related genes (CFHR1-5) are major determinants of AMD susceptibility, but their molecular consequences remain unclear. Here we demonstrate that FHR-4 plays a prominent role in AMD pathogenesis. We show that systemic FHR-4 levels are elevated in AMD (P-value = 7.1 × 10−6), whereas no difference is seen for FH. Furthermore, FHR-4 accumulates in the choriocapillaris, Bruch’s membrane and drusen, and can compete with FH/FHL-1 for C3b binding, preventing FI-mediated C3b cleavage. Critically, the protective allele of the strongest AMD-associated CFH locus variant rs10922109 has the highest association with reduced FHR-4 levels (P-value = 2.2 × 10−56), independently of the AMD-protective CFHR1–3 deletion, and even in those individuals that carry the high-risk allele of rs1061170 (Y402H). Our findings identify FHR-4 as a key molecular player contributing to complement dysregulation in AMD.

8 November 2019 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
PDF file
WZWioleta Milena Zelek
Wioleta Milena Zelek
DFDina Fathalla
Dina Fathalla
AMAngharad Morgan
Angharad Morgan
STSamuel Touchard
Samuel Touchard
SLSamantha Loveless
Samantha Loveless
BMB Paul Morgan
B Paul Morgan
Background: Multiple sclerosis (MS) can be difficult to differentiate from other demyelinating diseases, notably neuromyelitis optica spectrum disorder (NMOSD). We previously showed that NMOSD is distinguished from MS by plasma complement biomarkers. Objective: Here, we measure cerebrospinal fluid (CSF) complement proteins in MS, NMOSD and clinically isolated syndrome (CIS), a neurological episode that may presage MS, to test whether these distinguish NMOSD from MS and CIS. Materials and methods: CSF (53 MS, 17 CIS, 11 NMOSD, 35 controls) was obtained; complement proteins (C4, C3, C5, C9, C1, C1q, Factor B (FB)), regulators (Factor I (FI), Factor H (FH), FH-Related Proteins 1, 2 and 5 (FHR125), C1 Inhibitor (C1INH), Properdin) and activation products (terminal complement complex (TCC), iC3b) were quantified by ELISA and results expressed relative to CSF total protein (μg/mg). Results: Compared to control CSF, (1) levels of C4, C1INH and Properdin were elevated in MS; (2) TCC, iC3b, FI and FHR125 were increased in CIS; and (3) all complement biomarkers except TCC, FHR125, Properdin and C5 were higher in NMOSD CSF. A statistical model comprising six analytes (C3, C9, FB, C1q, FI, Properdin) plus age/gender optimally differentiated MS from NMOSD.

5 November 2022 in Journal of Controlled Release
Verified
Journal Article
Closed access
HGHytham H. Gadalla
Hytham H. Gadalla
SLSeongsoo Lee
Seongsoo Lee
HKHyungjun Kim
Hyungjun Kim
AAAbigail T. Armstrong
Abigail T. Armstrong
DFDina Fathalla
Dina Fathalla
YYYoon Yeo
Yoon Yeo